SCHEMBL2449045

SCHEMBL2449045

Cc1ccc(-c2cc(C(C)(C)C)cc3cc(N4CC[C@H](CNS(C)(=O)=O)C4)cnc23)c(=O)[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.40
AURKB Q96GD4 3/20 0.40
IRAK1 P51617 1/20 0.39
SMO Q99835 1/20 0.36
LDHA P00338 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CNR1 P21554 2/20 0.32
CNR2 P34972 2/20 0.32
ICAM1 P05362 1/20 0.32
JAK2 O60674 2/20 0.31
JAK1 P23458 2/20 0.31
TYK2 P29597 2/20 0.31
JAK3 P52333 2/20 0.31
RBP4 P02753 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452342 0.97 AURKA (0.43) AURKAAURKBIRAK1SMOLDHA
SCHEMBL3759266 0.90 IRAK1 (0.37) AURKAAURKBIRAK1SMOLDHA
SCHEMBL16143827 0.88 IRAK1 (0.40) AURKAAURKBIRAK1SMOLDHA
SCHEMBL1702776 0.88 EIF2AK4 (0.40) AURKAAURKBSMO
SCHEMBL2448007 0.86 AURKA (0.30) AURKAAURKB
SCHEMBL16143889 0.85 AURKA (0.43) AURKAAURKBIRAK1SMOLDHA
SCHEMBL1703030 0.83 KCNJ1 (0.31)
SCHEMBL2448595 0.82 AURKA (0.36) AURKAAURKBIRAK1SMOLDHA
SCHEMBL13046837 0.82 KDM4E (0.33) IRAK1KDM4EALDH1A1GAAMAPT
SCHEMBL12302433 0.77 ALDH1A1 (0.39) AURKAAURKBIRAK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP claimed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 US claimed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 AURKA 4099/4885AURKB 2982/4885IRAK1 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.